Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
|Articles|November 1, 2006
The Institute for OneWorld Health Receives BMGF Grant to Combat Diarrheal Disease
Silencing a Global Health Challenge that Kills Two Million Children a Year.
Advertisement
1 November 2006-The Institute for OneWorld Health (San Francisco, CA) will receive a $46.07 million grant from the Bill and Melinda Gates Foundation (BMGF) to explore alternative cures for diarrheal disease. This is the largest grant the BMGF has ever awarded to an organization to address diarrheal disease, the overlooked global health challenge that kills more than two million children annually.
The grant is focused on identifying and developing new approaches to curing diarrheal disease, a chronic and pervasive killer whose bacterial sources are varied, but widespread in the developing world.
Advertisement
Related to this article
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, identifies three recurring failure modes in AI governance frameworks—and explains why responsible AI must be an ongoing operating discipline, not a one-time approval gate.
CRIO’s chief innovation officer, Mike Wenger touches on the two ways sites get AI adoption wrong.
CRIO’s Mike Wenger, speaker at this year's SCRS summit, maps how sites are actually deploying AI post-pilot stage.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, explains why the real advantage of faster data isn’t speed—it’s shortening the distance between signals, human judgment, and the next best action.
In today’s ACT Brief, we examine how AI is moving into continuous clinical operating models, how trust is built into oncology real-world evidence, and how the FDA approved a self-administered option for thyroid eye disease.
Paradigm’s Kurt Mussina discusses why scale should drive operational efficiency, not consolidation into single-site studies.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where AI Governance in Clinical Development Falls Short
2
2026 SCRS Global Site Solutions Summit: What's the Biggest Mistake Sites or Sponsors Make When Implementing Advanced Al?
3
Syneos Health, Optum Partner on Adaptive Clinical Development Model
4
Building Trust Into Oncology Real-World Evidence: Q&A with Saamir Pasha and Carole Berini, Ontada
5